Kenneth L. Zeitzer

Thomas Jefferson University Hospital — United States

Medicine · Health Sciences

15h-index1.5kcitations45works4.42yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Prostate Cancer Treatment and Research(35), Prostate Cancer Diagnosis and Treatment(32), Advanced Radiotherapy Techniques(13), Cancer, Lipids, and Metabolism(5), Hormonal and reproductive studies(4)

Publications45 total

Long-Term Results of NRG/RTOG 9601, a Randomized Trial of Radiation With or Without Antiandrogens in Patients Receiving Salvage Prostate Bed Radiation Therapy Postprostatectomy
International Journal of Radiation Oncology*Biology*Physics·2025· 5 citedOpen Access
Phase II Study of Low-Dose Paclitaxel and Cisplatin in Combination With Split-Course Concomitant Twice-Daily Reirradiation in Recurrent Squamous Cell Carcinoma of the Head and Neck: Long-term Follow-up of NRG Oncology RTOG 9911
International Journal of Radiation Oncology*Biology*Physics·2025Open Access
Prognostic Impact of Lymph Node Yield in a Phase III Clinical Trial (NRG/RTOG 9601) of Prostate Cancer Patients Treated With Salvage Radiation Following Prostatectomy
The Prostate·2025Open Access
Biopsy-based Basal-luminal Subtyping Classifier in High-risk Prostate Cancer: A Combined Analysis of the NRG Oncology/RTOG 9202, 9413, and 9902 Phase 3 Trials
European Urology Oncology·2024· 1 cited
Cardiovascular Mortality and Duration of Androgen Deprivation in Locally Advanced Prostate Cancer: Long-term Update of NRG/RTOG 9202
European Urology Focus·2024· 3 citedOpen Access
External Validation of a Digital Pathology-based Multimodal Artificial Intelligence Architecture in the NRG/RTOG 9902 Phase 3 Trial
European Urology Oncology·2024· 22 citedOpen Access
Long-term results of radiation with or without anti-androgens (AAT) in patients receiving salvage prostate bed radiation therapy (sRT) post prostatectomy.
Journal of Clinical Oncology·2024
Association of Radiotherapy Duration With Clinical Outcomes in Patients With Esophageal Cancer Treated in NRG Oncology Trials
JAMA Network Open·2023· 13 citedOpen Access
A Once-Thought Lipoma Turned Malignant Chondroid Syringoma
Cureus·2023Open Access
Effects of Androgen Deprivation Therapy on Prostate Cancer Outcomes According to Competing Event Risk: Secondary Analysis of a Phase 3 Randomised Trial
European Urology·2023· 10 citedOpen Access
Analysis of a Biopsy-Based Genomic Classifier in High-Risk Prostate Cancer: Meta-Analysis of the NRG Oncology/Radiation Therapy Oncology Group 9202, 9413, and 9902 Phase 3 Randomized Trials
International Journal of Radiation Oncology*Biology*Physics·2022· 46 citedOpen Access
1378P Biopsy-based basal-luminal subtyping classifier in high-risk prostate cancer: Analysis of the NRG Oncology/RTOG 9202, 9413, and 9902 randomized phase III trials
Annals of Oncology·2022· 1 citedOpen Access
Biochemical Failure Is Not a Surrogate End Point for Overall Survival in Recurrent Prostate Cancer: Analysis of NRG Oncology/RTOG 9601
Journal of Clinical Oncology·2022· 24 citedOpen Access
Impact of lymph node yield at prostatectomy on outcomes in NRG/RTOG 9601.
Journal of Clinical Oncology·2022
Metastasis-Free Survival, but Not Biochemical Failure, is a Strong Surrogate Endpoint for Overall Survival in Recurrent Prostate Cancer: Analysis of NRG Oncology/RTOG 9601
International Journal of Radiation Oncology*Biology*Physics·2020
Gleason pattern 5 is associated with an increased risk for metastasis following androgen deprivation therapy and radiation: An analysis of RTOG 9202 and 9902
Radiotherapy and Oncology·2019· 9 citedOpen Access
Prostate-Specific Antigen After Neoadjuvant Androgen Suppression in Prostate Cancer Patients Receiving Short-Term Androgen Suppression and External Beam Radiation Therapy: Pooled Analysis of Four NRG Oncology Radiation Therapy Oncology Group Randomized Clinical Trials
International Journal of Radiation Oncology*Biology*Physics·2019· 13 citedOpen Access
Time Interval to Biochemical Failure as a Surrogate End Point in Locally Advanced Prostate Cancer: Analysis of Randomized Trial NRG/RTOG 9202
Journal of Clinical Oncology·2018· 29 cited
Sequence of hormonal therapy and radiotherapy field size in unfavourable, localised prostate cancer (NRG/RTOG 9413): long-term results of a randomised, phase 3 trial
The Lancet Oncology·2018· 224 citedOpen Access
Risk factors for late bowel and bladder toxicities in NRG Oncology prostate cancer trials of high-risk patients: A meta-analysis of physician-rated toxicities
Advances in Radiation Oncology·2018· 3 citedOpen Access
page 1 of 3Next →

Frequent Co-authors

Howard M. Sandler(30), Seth A. Rosenthal(24), Thomas M. Pisansky(18), William U. Shipley(16), Luís Souhami(16), Stephanie L. Pugh(11), Mack Roach(11), Eric M. Horwitz(11), Jason A. Efstathiou(11), Felix Y. Feng(10), Elizabeth Gore(10), Christopher U. Jones(10), C.A. Lawton(10), Jean-Paul Bahary(10), Alan C. Hartford(9), Alexander G. Balogh(8), Himanshu Lukka(7), Oliver Sartor(7), R.D. Lovett(7), Jeff M. Michalski(7)